Updates in Screening and Surveillance for Barrett’s Esophagus
We have become excellent at treating Barrett’s esophagus (BE) related neoplasia. But to reduce the instance of esophageal adenocarcinoma (EAC) we need to increase the population under surveillance and leverage risk stratification tools to personalize the management of non-dysplastic BE.
Barrett’s Esophagus Panel: Establishing Individual Patient Risk for Progression to Esophageal Cancer
Understand how TissueCypher® predicts future development of HGD/EAC in patients with BE. Impacts patient-care decisions as demonstrated by case studies.
TissueCypher® Objectively Risk Stratifies Barrett’s Esophagus Patients with Low-Grade Dysplasia*
Pathologic diagnosis is highly variable, even among experts, while TissueCypher® provides objective risk stratification. TissueCypher outperformed community and expert pathologists for sensitivity and detected >50% of NDBE progressors who were down-staged (i.e. missed).
Prediction of Progression in Barrett’s Esophagus Using a Tissue Systems Pathology Test: A Pooled Analysis of International Multicenter Studies*
Addition of TissueCypher® significantly increases the accuracy and power of risk prediction providing for personalized management of BE patients.
Risk Stratification and Management of Dysplastic Barrett’s Esophagus*
Risk stratification is important in managing BE patients and biomarker assays such as TissueCypher® are “ready for Prime Time” in identifying patients at high risk for progression.
* All content is derived from presentations and similar offerings made at Digestive Disease Week® 2021 and is presented with permission of DDW, LLC.
Barrett’s Esophagus Panel: Predicting Progression in Barrett’s Esophagus Recent Advances Webinar
A panel discussion on the clinical challenges associated with predicting progression to esophageal adenocarcinoma in patients with Barrett’s esophagus.
